The board of directors of PW Medtech Group Limited announced that based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2023, the Group is expected to record (i) a net profit in the range of RMB 90 million to RMB 100 million for the six months ended June 30, 2023, representing an increase of 25.9% to 39.9% as compared to that of approximately RMB 71.5 million for the same period in 2022, and (ii) a profit attributable to owners of the Company in the range of RMB 63 million to RMB 73 million for the six months ended June 30, 2023, representing an increase of 4.0% to 20.5% as compared to that of approximately RMB 60.6 million for the same period in 2022. Such increase is primarily due to a significant increase in the profit contributed by the Group's blood purification business.